A technician at Regeneron Prescription drugs headquarters in Tarrytown, New York.
Mike Segar | Reuters
Regeneron Prescription drugs stated on Monday it started late-stage medical trials to evaluate the effectiveness of its antibody cocktail in stopping and treating Covid-19.
The trial, run collectively with the Nationwide Institute of Allergy and Infectious Illnesses, would check the remedy’s potential to forestall an infection in those that have had shut publicity to a Covid-19 affected person.